Compare Global X Data Center & Digital Infra ETF (DTCR) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Data Center & Digital Infra ETF vs Dyne Therapeutics Inc. Common Stock — how do they compare? Global X Data Center & Digital Infra ETF trades at $25.99 (market cap $2.11B), while Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Global X Data Center & Digital Infra ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Data Center & Digital Infra ETF for 17 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DTCR | DYN | |
|---|---|---|
Market Cap | $2.11B | $2.86B |
Volume | 655,653 | 3,341,579 |
Sector | Sector/Thematic | Health |
52-Week High | $32.46 | $26.78 |
52-Week Low | $19.73 | $14.60 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $2.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DTCR trades at $27.33, down 1.44% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Recent news highlights DTCR's position as a key ETF for AI infrastructure exposure, with coverage emphasizing its blend of real estate stability and growth from digital infrastructure sectors. The ETF has gained attention as a picks-and-shovels play in the AI boom.
The outlook for DTCR appears favorable given sustained AI infrastructure investment, though risks include sector volatility and interest rate sensitivity. Analyst sentiment remains positive with buy recommendations citing long-term growth potential from diversified technology and real estate holdings.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Data Center & Digital Infra ETF
Global X Data Center & Digital Infrastructure ETF seeks exposure to companies involved in data centers and digital infrastructure. Its holdings span areas such as digital infrastructure, networking, and related real estate.
Read more on DTCR →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
